Sending an Authorization Request Through PrescribeIT® for a Split Rx

As prescriptions in a Split Rx group are components of what was originally a single PrescribeIT® prescription, authorization requests for a Split Rx must reflect what was originally prescribed.

When attempting to generate an authorization request for a Split Rx prescription, a prompt appears asking if you want to send the authorization request for all prescriptions in the split. Depending on what you select in the prompt, other prescriptions in the split appear in the Authorization Request Form window for sending or as informational only.

Select the dropdowns to learn how to send an authorization request for a split group.

PrescribeIT® Messages

Once an authorization request is sent via PrescribeIT®, all prescriptions associated with the split are displayed in the PrescribeIT® Messages > Pending tab. The Drug column will indicate if a prescription was informational. The prescriptions will move to the PrescribeIT® Messages > Completed tab once a response is received.

Hover over the Split Rx indicator to view all the drugs that are part of the split.

If an authorization request fails or is rejected by PrescribeIT®, all prescriptions associated to the split are marked as Failed and you can detail any one of them to view the failure.

Authorization Request Scenarios

This section outlines different scenarios you may encounter when sending an authorization request for a Split Rx group.

Select the dropdowns to learn more.

Splitting an Authorization Request Response

Once you receive an Authorization Request Response from the prescriber for the Split Rx, you can process and split it again if needed. An Authorization Request Response is based on the original unsplit medication request. Therefore, it will not be automatically split when processed into Intake.

After splitting the PrescribeIT® prescription, use the Profile button in the Intake window to reauthorize the existing prescription on the Patient Profile. This will save you data entry time.